Abstract :

Health Technology Assessment (HTA) is an important multidisciplinary process for health policymakers and decision-makers to evaluate a range of health technologies, medical devices, and pharmaceuticals to enable the efficiency with finite healthcare budgets. It aids the effectiveness and fairness in decision making. HTA is a mechanism to introduce a value for money in the healthcare system. HTA methods are evolving, and their applications are diverse.  This review introduces fundamental aspects and issues of dynamic concept of HTA.

---

Keywords :

Evidence-based decision making, Health policy., Health Technology Assessment, Hospital based HTA, HTA methods

---

References :

1. Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace. 2011 May 1;13(suppl 2):ii49–53.
2. Banta D, Jonsson E. History of HTA: Introduction. Int J Technol Assess Health Care. 2009 Jul;25(S1):1–6.
3. United States Congress Office of Technology Assessment. Development of Medical Technology: Opportunities for Assessment [Internet]. 1976. Available from: https://www.princeton.edu/~ota/disk3/1976/7617/7617.PDF
4. Office of Technology Assessment. Policy Implications of the Computed Tomography (CT) Scanner: An Update [Internet]. 1981. Available from: https://ota.fas.org/reports/8122.pdf
5. Office of Technology Assessment. The Implications of Cost-Effectiveness Analysis of Medical Technology: Methodological Issues and Literature Review [Internet]. U.S. Government Printing Office Washington, D.C.; 1980. Available from: https://ota.fas.org/reports/8013.pdf
6. Office of Technology Assessment. Assessing the Efficacy and Safety of Medical Technologies [Internet]. U.S. Government Printing Office Washington; 1978. Available from: https://ota.fas.org/reports/7805.pdf
7. Council on Health Care Technology (Institute of Medicine), editor. Consensus development at the NIH: improving the program: report of a study. Washington, D.C: National Academy Press; 1990. 81 p.
8. Banta D. The development of health technology assessment. Health Policy. 2003 Feb;63(2):121–32.
9. Jonsson E. History of health technology assessment in Sweden. Int J Technol Assess Health Care. 2009 Jul;25(S1):42–52.
10. Banta D, Kristensen FB, Jonsson E. A history of health technology assessment at the European level. Int J Technol Assess Health Care. 2009 Jul;25(S1):68–73.
11. Velasco Garrido M, World Health Organization, European Observatory on Health Systems and Policies, editors. Health technology assessment and health policy-making in Europe: current status, challenges, and potential. Copenhagen: World Health Organization on behalf of the European Observatory on Health Systems and Policies; 2008. 181 p. (Observatory studies series).
12. Fontrier AM, Visintin E, Kanavos P. Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries. PharmacoEconomics – Open. 2022 May;6(3):315–28.
13. Akehurst RL, Abadie E, Renaudin N, Sarkozy F. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value Health. 2017 Jan;20(1):67–76.
14. Novaes HMD, Soárez PC de. Health technology assessment (HTA) organizations: dimensions of the institutional and political framework. Cad Saúde Pública [Internet]. 2016 [cited 2022 Sep 9];32(suppl 2). Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2016001405008&lng=en&tlng=en
15. Oortwijn W, Broos P, Vondeling H, Banta D, Todorova L. MAPPING OF HEALTH TECHNOLOGY ASSESSMENT IN SELECTED COUNTRIES. Int J Technol Assess Health Care. 2013 Oct;29(4):424–34.
16. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018 Jan;19(1):123–52.
17. Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess. 2005 Nov 15;1:Doc09.
18. Ciani O, Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des Devel Ther. 2014 Nov;2273.
19. Battista RN, Côté B, Hodge MJ, Husereau D. Health technology assessment in Canada. Int J Technol Assess Health Care. 2009 Jul;25(S1):53–60.
20. Wolbring G. The triangle of enhancement medicine, disabled people, and the concept of health: a new challenge for HTA, health research, and health policy [Internet]. University of Alberta Libraries; 2005 [cited 2022 Sep 8]. Available from: https://era.library.ualberta.ca/files/bmp48sc97n
21. Busse R, Orvain J, Velasco M, Perleth M, Drummond M, G¨rtner F, et al. BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS: Working Group 4 Report. Int J Technol Assess Health Care. 2002 Apr;18(2):361–422.
22. Healy J. Health sector reform in Central and Eastern Europe: the professional dimension. Health Policy Plan. 1997 Dec 1;12(4):286–95.
23. World Health Organization. WHO study group on tobacco product regulation: report on the scientific basis of tobacco product regulation: eighth report of a WHO study group [Internet]. Geneva: World Health Organization; 2021 [cited 2022 Sep 8]. (WHO technical report series;1029). Available from: https://apps.who.int/iris/handle/10665/341113
24. Glassman A, Chalkidou K. Priority-setting in health: building institutions for smarter public spending. Center for Global Development.; 2012.
25. Gerhardus A, Dintsios CM. The impact of HTA reports on health policy: a systematic review. GMS Health Technol Assess. 2005 Nov 2;1:Doc02.
26. World Health Organization, editor. Health for all targets: the health policy for Europe. Updated ed., Sept. 1991. Copenhagen: The Organization, The Office; 1993. 228 p. (European health for all series).
27. Wild C, Stricka M, Patera N. Guidance for the development of a National HTA-strategy. Health Policy Technol. 2017 Sep;6(3):339–47.
28. Youngkong S. Application of HTA research on policy decision-making. J Med Assoc Thail Chotmaihet Thangphaet. 2014 May;97 Suppl 5:S119-126.
29. Berger ML, International Society for Pharmacoeconomics and Outcomes Research, editors. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2003. 264 p.
30. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996 Jan 13;312(7023):71–2.
31. Ferrario L, Foglia E, Garagiola E, Pacelli V, Cenderello G, Di Biagio A, et al. The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. J Prev Med Hyg. 2020 Aug 31;E451 Pages.
32. Elbarbary M. Health technology assessment (HTA) in cardiac field. J Saudi Heart Assoc. 2010 Apr;22(2):77–84.
33. Gałązka-Sobotka M, Frączkiewicz-Wronka A, Kowalska-Bobko I, Kelm H, Szymaniec-Mlicka K. HB-HTA as an implementation problem in Polish health policy. Mordaunt DA, editor. PLOS ONE. 2021 Sep 24;16(9):e0257451.
34. Margotti AE, Garcia R. Hospital based HTA Model by Structuring the Decision Making Process Regarding the Medical Device Incorporation. In: Biomedical Engineering / 765: Telehealth / 766: Assistive Technologies [Internet]. Innsbruck, Austria: ACTAPRESS; 2012 [cited 2022 Sep 9]. Available from:

http://www.actapress.com/PaperInfo.aspx?paperId=453273

35. Rashiq S, Barton P, Harstall C, Schopflocher D, Taenzer P, the Alberta Ambassador Program Team. The Alberta Ambassador Program: delivering Health Technology Assessment results to rural practitioners. BMC Med Educ. 2006 Dec;6(1):21.
36. Carlsson P, Jonsson E, Werkö L, Banta D. HEALTH TECHNOLOGY ASSESSMENT IN SWEDEN. Int J Technol Assess Health Care. 2000 Apr;16(2):560–75.
37. Kidholm K, Ehlers L, Korsbek L, Kjærby R, Beck M. Assessment of the quality of mini-HTA. Int J Technol Assess Health Care. 2009 Jan;25(01):42–8.
38. Ehlers L, Vestergaard M, Kidholm K, Bonnevie B, Pedersen PH, Jørgensen T, et al. Doing mini–health technology assessments in hospitals: A new concept of decision support in health care? Int J Technol Assess Health Care. 2006 Jul;22(3):295–301.
39. Govender M, Mueller DB, Basu D. Purchasing of medical equipment in public hospitals: the mini-HTA tool. S Afr Med J [Internet]. 2011;101(11). Available from: http://www.scielo.org.za/scielo.php?pid=S0256-95742011001100018&script=sci_arttext&tlng=es

40. Gagnon MP, Desmartis M, Gagnon J, St-Pierre M, Gauvin FP, Rhainds M, et al. Introducing the patient’s perspective in hospital health technology assessment (HTA): the views of HTA producers, hospital managers and patients. Health Expect. 2014 Dec;17(6):888–900.
41. McGregor M, Brophy JM. End-user involvement in health technology assessment (HTA) development: A way to increase impact. Int J Technol Assess Health Care. 2005 Apr;21(2):263–7.
42. Cicchetti A, Marchetti M, Iacopino V, D’Amico G, Sampietro-Colom L. Organizational Models of Hospital Based HTA: Empirical Evidence from Adhophta European Project. Value Health. 2015 Nov;18(7):A560–1.
43. Gagnon MP, Desmartis M, Poder T, Witteman W. Effects and repercussions of local/hospital-based health technology assessment (HTA): a systematic review. Syst Rev. 2014 Dec;3(1):129.
44. Yuba TY, Novaes HMD, de Soárez PC. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations. Health Res Policy Syst. 2018 Dec;16(1):40.
45. Ciani O, Federici C, Tarricone R. Current and Future Trends in the HTA of Medical Devices. In: Kyriacou E, Christofides S, Pattichis CS, editors. XIV Mediterranean Conference on Medical and Biological Engineering and Computing 2016 [Internet]. Cham: Springer International Publishing; 2016 [cited 2022 Sep 12]. p. 1345–8. (IFMBE Proceedings; vol. 57). Available from: http://link.springer.com/10.1007/978-3-319-32703-7_258
46. Nicod E, Annemans L, Bucsics A, Lee A, Upadhyaya S, Facey K. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. Health Policy. 2019 Feb;123(2):140–51.
47. Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014 May;15(4):335–40.
48. Kanavos P, Nicod E. What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward. Value Health. 2012 Dec;15(8):1182–4.
49. Department of Health Technology Assessment, Faculty of Public Health, Medical University – Sofia, Bulgaria, Georgiev S, Yanakieva A, Department of Health Technology Assessment, Faculty of Public Health, Medical University – Sofia, Bulgaria, Priftis S, Student, Faculty of Public Health, Medical University – Sofia, Bulgaria. SOCIOECONOMIC CHARACTERISTICS OF COUNTRIES BASED ON THE PRESENCE OF HTA AGENCY. J IMAB – Annu Proceeding Sci Pap. 2017 Aug 2;23(3):1637–40.
50. Mathew JL. KNOW ESSENTIALS: A tool for informed decisions in the absence of formal HTA systems. Int J Technol Assess Health Care. 2011 Apr;27(2):139–50.
51. MacQuilkan K, Baker P, Downey L, Ruiz F, Chalkidou K, Prinja S, et al. Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa. Glob Health Action. 2018 Jan;11(1):1527556.
52. Gamage AU, Abeysena C. Health Technology Assessment (HTA) and health policy making: a narrative review. J Coll Community Physicians Sri Lanka. 2020 Nov 30;26(3):175.
53. Babidge WJ. Global HTA: Past, present, and future. Med Writ. 2021 Sep;30(3).
54. Pearson H. How COVID broke the evidence pipeline. Nature. 2021 May 13;593(7858):182–5.
55. Pongiglione B, Torbica A, Blommestein H, de Groot S, Ciani O, Walker S, et al. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. Int J Technol Assess Health Care. 2021;37(1):e62.